Sympathetic responses to atrial natriuretic peptide in patients with congestive heart failure.
Previous studies have shown that atrial natriuretic peptide (ANP) has relative sympathoinhibitory effects that are of potential benefit in patients with congestive heart failure (CHF). In this study, cardiac and systemic sympathetic responses to ANP were evaluated and compared with responses to sodium nitroprusside (SNP) in patients with CHF. Right- and left-heart hemodynamics were obtained simultaneously with cardiac (CANESP) and total body (TBNESP) norepinephrine spillover; these were measured by using the radiotracer technique. Reductions in arterial blood pressure and cardiac filling pressures were similar with both drugs. ANP and SNP caused a significant and similar increase in TBNESP. Mean values for CANESP did not change in either group, but the response of individual patients was dependent on the effect on diastolic blood pressure (r = -0.71, p<0.01). These results do not provide evidence for a sympathoinhibitory effect of ANP, but suggest that in patients with CHF, cardiac sympathoexcitatory response to arterial baroreceptor unloading may be countered by a potential sympathoinhibitory effect caused by a reduction in cardiac filling pressures. In the setting of CHF, vasodilator therapy may decrease cardiac sympathetic activity if systemic hypotension is avoided.
Azevedo
E R
ER
Department of Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada.
Newton
G E
GE
Parker
A B
AB
Floras
J S
JS
Parker
J D
JD
D009320:Atrial Natriuretic Factor / Q000627:therapeutic use*; D002395:Catecholamines / Q000097:blood; D003326:Coronary Circulation / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009599:Nitroprusside / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000187:drug effects*; D013565:Sympatholytics / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
D002395:Catecholamines; D013565:Sympatholytics; D014665:Vasodilator Agents; D009599:Nitroprusside; D009320:Atrial Natriuretic Factor; D009638:Norepinephrine